PL3366688T3 - Podstawione pirazolopirymidyny jako aktywatory glukocerebrozydazy - Google Patents

Podstawione pirazolopirymidyny jako aktywatory glukocerebrozydazy

Info

Publication number: PL3366688T3
Authority: PL; Poland
Prior art keywords: substituted pyrazolopyrimidines; glucocerebrosidase; activators; glucocerebrosidase activators; pyrazolopyrimidines
Prior art date: 2010-12-08

Application number

PL18165005T

Other languages

English (en)

Inventor

Juan Jose Marugan

Noel Southall

M. Ehud GOLDIN

Samarjit Patnaik

Ellen Sidransky

Omid Motabar

Wendy Westbrook

Wei Zheng

Original Assignee

The U.S.A. As Represented By The Secretary, Department Of Health And Human Services

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2010-12-08

Filing date

2011-12-08

Publication date

2022-05-23

2011-12-08 Application filed by The U.S.A. As Represented By The Secretary, Department Of Health And Human Services filed Critical The U.S.A. As Represented By The Secretary, Department Of Health And Human Services

2022-05-23 Publication of PL3366688T3 publication Critical patent/PL3366688T3/pl

Links

APXRHPDHORGIEB-UHFFFAOYSA-N 1H-pyrazolo[4,3-d]pyrimidine Chemical class N1=CN=C2C=NNC2=C1 APXRHPDHORGIEB-UHFFFAOYSA-N 0.000 title 1
102000004547 Glucosylceramidase Human genes 0.000 title 1
108010017544 Glucosylceramidase Proteins 0.000 title 1
239000012190 activator Substances 0.000 title 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Medicinal Chemistry (AREA)
Animal Behavior & Ethology (AREA)
Life Sciences & Earth Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Epidemiology (AREA)
Bioinformatics & Cheminformatics (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Engineering & Computer Science (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Nitrogen Condensed Heterocyclic Rings (AREA)

PL18165005T 2010-12-08 2011-12-08 Podstawione pirazolopirymidyny jako aktywatory glukocerebrozydazy PL3366688T3 (pl)

Applications Claiming Priority (4)

Application Number	Priority Date	Filing Date	Title
US42094610P	2010-12-08	2010-12-08
PCT/US2011/063928 WO2012078855A1 (en)	2010-12-08	2011-12-08	Substituted pyrazolopyrimidines as glucocerebrosidase activators
EP11810714.3A EP2649075B1 (en)	2010-12-08	2011-12-08	Substituted pyrazolopyrimidines as glucocerebrosidase activators
EP18165005.2A EP3366688B1 (en)	2010-12-08	2011-12-08	Substituted pyrazolopyrimidines as glucocerebrosidase activators

Publications (1)

Publication Number	Publication Date
PL3366688T3 true PL3366688T3 (pl)	2022-05-23

Family

ID=45498099

Family Applications (2)

Application Number	Title	Priority Date	Filing Date
PL18165005T PL3366688T3 (pl)	2010-12-08	2011-12-08	Podstawione pirazolopirymidyny jako aktywatory glukocerebrozydazy
PL11810714T PL2649075T3 (pl)	2010-12-08	2011-12-08	Podstawione pirazolopirymidyny jako aktywatory glukocerebrozydazy

Family Applications After (1)

Application Number	Title	Priority Date	Filing Date
PL11810714T PL2649075T3 (pl)	2010-12-08	2011-12-08	Podstawione pirazolopirymidyny jako aktywatory glukocerebrozydazy

Country Status (24)

Country	Link
US (3)	US9353117B2 (pl)
EP (2)	EP3366688B1 (pl)
JP (1)	JP6154746B2 (pl)
KR (1)	KR101931224B1 (pl)
CN (1)	CN103534255B (pl)
AU (1)	AU2011338377B2 (pl)
BR (1)	BR112013014242B1 (pl)
CA (1)	CA2820362C (pl)
CY (1)	CY1125186T1 (pl)
DK (2)	DK2649075T3 (pl)
ES (2)	ES2912284T3 (pl)
HR (1)	HRP20220512T1 (pl)
HU (1)	HUE038635T2 (pl)
IL (2)	IL226767B (pl)
LT (1)	LT3366688T (pl)
MX (2)	MX385600B (pl)
PL (2)	PL3366688T3 (pl)
PT (2)	PT3366688T (pl)
RS (1)	RS63320B1 (pl)
RU (1)	RU2603637C2 (pl)
SI (2)	SI2649075T1 (pl)
TR (1)	TR201810523T4 (pl)
WO (1)	WO2012078855A1 (pl)
ZA (1)	ZA201304215B (pl)

Families Citing this family (57)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
PL3366688T3 (pl)	2010-12-08	2022-05-23	The U.S.A. As Represented By The Secretary, Department Of Health And Human Services	Podstawione pirazolopirymidyny jako aktywatory glukocerebrozydazy
WO2012178125A1 (en)	2011-06-22	2012-12-27	Vertex Pharmaceuticals Incorporated	Compounds useful as inhibitors of atr kinase
AU2012272815B2 (en) *	2011-06-22	2017-09-07	The General Hospital Corporation	Treatment of proteinopathies
AP2013007331A0 (en)	2011-06-24	2013-12-31	Amgen Inc	TRPM8 antagonists and their use in treatments
EP2723718A1 (en)	2011-06-24	2014-04-30	Amgen Inc.	Trpm8 antagonists and their use in treatments
KR20140077963A (ko) *	2011-10-20	2014-06-24	글락소스미스클라인 엘엘씨	시르투인 조절제로서의 치환된 비시클릭 아자-헤테로사이클 및 유사체
US8940742B2 (en)	2012-04-10	2015-01-27	Infinity Pharmaceuticals, Inc.	Heterocyclic compounds and uses thereof
US8952009B2 (en)	2012-08-06	2015-02-10	Amgen Inc.	Chroman derivatives as TRPM8 inhibitors
LT3418281T (lt)	2012-12-07	2021-01-11	Vertex Pharmaceuticals Inc.	Pirazolo[1,5-a]pirimidinai, naudotini kaip atr kinazės inhibitoriai, skirti vėžinių ligų gydymui
EP2970289A1 (en)	2013-03-15	2016-01-20	Vertex Pharmaceuticals Inc.	Compounds useful as inhibitors of atr kinase
WO2014143240A1 (en)	2013-03-15	2014-09-18	Vertex Pharmaceuticals Incorporated	Fused pyrazolopyrimidine derivatives useful as inhibitors of atr kinase
EP2970288A1 (en)	2013-03-15	2016-01-20	Vertex Pharmaceuticals Incorporated	Compounds useful as inhibitors of atr kinase
WO2015051241A1 (en)	2013-10-04	2015-04-09	Infinity Pharmaceuticals, Inc.	Heterocyclic compounds and uses thereof
EP3964507A1 (en)	2013-10-04	2022-03-09	Infinity Pharmaceuticals, Inc.	Heterocyclic compounds and uses thereof
HUE046727T2 (hu)	2013-12-06	2020-03-30	Vertex Pharma	Az ATR-kináz inhibitoraként használható vegyület, 2-amino-6-fluoro-N-[5-fluoro-piridin-3-IL]-pirazolo-[1,5-A]-pirimidin-3-karboxamid, ennek elõállítása, különbözõ szilárd formái és ezek radioaktív nyomjelzett származékai
CN106456628A (zh)	2014-03-19	2017-02-22	无限药品股份有限公司	用于治疗PI3K‑γ介导的障碍的杂环化合物
ES2777608T3 (es)	2014-06-05	2020-08-05	Vertex Pharma	Derivados radiomarcados de un compuesto de 2-amino-6-fluoro-N-[5-fluoro-piridin-3-il]-pirazolo[1,5-a]pirimidin-3-carboxamida útiles como inhibidores de ATR cinasa, la preparación de dicho compuesto y diferentes formas sólidas del mismo
US11179394B2 (en)	2014-06-17	2021-11-23	Vertex Pharmaceuticals Incorporated	Method for treating cancer using a combination of Chk1 and ATR inhibitors
WO2016054491A1 (en)	2014-10-03	2016-04-07	Infinity Pharmaceuticals, Inc.	Heterocyclic compounds and uses thereof
EP3215505B1 (en)	2014-11-03	2019-07-24	Bayer Pharma Aktiengesellschaft	Piperidinylpyrazolopyrimidinones and their use
EP3215511B1 (en) *	2014-11-06	2024-04-17	Bial-R&D Investments, S.A.	Substituted pyrazolo(1,5-a)pyrimidines and their use in the treatment of medical disorders
WO2016073889A1 (en)	2014-11-06	2016-05-12	Lysosomal Therapeutics Inc.	Substituted imidazo[1,5-a]pyrimidines and their use in the treatment of medical disorders
US20180185368A1 (en)	2014-11-06	2018-07-05	Lysosomal Therapeutics Inc.	Substituted pyrrolo[1,2-a]pyrimidines and their use in the treatment of medical disorders
WO2017004408A1 (en)	2015-07-01	2017-01-05	Northwestern University	Substituted 4-methyl-pyrrolo[1.2-a]pyrimidine-8-carboxamide compounds and uses thereof for modulating glucocerebrosidase activity
US20190092789A1 (en) *	2015-09-04	2019-03-28	Lysosomal Therapeutics Inc.	Heterobicyclic pyrimidinone compounds and their use in the treatment of medical disorders
WO2017040879A1 (en) *	2015-09-04	2017-03-09	Lysosomal Therapeutics Inc.	Thiazolo(3,2-a) pyrimidinone and other heterobicyclic pyrimidinone compounds for use in medical therapy
CN114230571B (zh)	2015-09-14	2025-07-08	无限药品股份有限公司	异喹啉酮的固体形式、其制备方法、包含其的组合物及其使用方法
US11464774B2 (en)	2015-09-30	2022-10-11	Vertex Pharmaceuticals Incorporated	Method for treating cancer using a combination of DNA damaging agents and ATR inhibitors
WO2017161137A1 (en) *	2016-03-16	2017-09-21	Lysosomal Therapeutics Inc.	Methods and compositions for treating a neurodegenerative disorder in a sphingotyped subject
WO2017161116A1 (en)	2016-03-17	2017-09-21	Infinity Pharmaceuticals, Inc.	Isotopologues of isoquinolinone and quinazolinone compounds and uses thereof as pi3k kinase inhibitors
WO2017176961A1 (en)	2016-04-06	2017-10-12	Lysosomal Therapeutics Inc.	Imidazo [1,5-a]pyrimidinyl carboxamide compounds and their use in the treatment of medical disorders
MX388912B (es) *	2016-04-06	2025-03-20	Lysosomal Therapeutics Inc	Compuestos de pirrol[1,2-a]pirimidinil carboxamida y su uso en el tratamiento de trastornos médicos
KR20180133461A (ko) *	2016-04-06	2018-12-14	리소소말 테라퓨틱스 인크.	피라졸로[1,5-a]피리미디닐 카르복스아미드 화합물 및 의학적 장애의 치료에서의 그의 용도
WO2017192931A1 (en)	2016-05-05	2017-11-09	Lysosomal Therapeutics Inc.	SUBSTITUTED IMDAZO[1,2-α]PYRIDINES, SUBSTITUTED IMIDAZO[1,2-α]PYRAZINES, RELATED COMPOUNDS, AND THEIR USE IN THE TREATMENT OF MEDICAL DISORDERS
WO2017192930A1 (en)	2016-05-05	2017-11-09	Lysosomal Therapeutics Inc.	SUBSTITUTED IMIDAZO[1,2-b]PYRIDAZINES, SUBSTITUTED IMIDAZO[1,5-b]PYRIDAZINES, RELATED COMPOUNDS, AND THEIR USE IN THE TREATMENT OF MEDICAL DISORDERS
WO2017192929A1 (en) *	2016-05-05	2017-11-09	Lysosomal Therapeutics Inc.	SUBSTITUTED PYRROLO[1,2-α]TRIAZINES AND RELATED COMPOUNDS AND THEIR USE IN THE TREATMENT OF MEDICAL DISORDERS
US10919914B2 (en)	2016-06-08	2021-02-16	Infinity Pharmaceuticals, Inc.	Heterocyclic compounds and uses thereof
WO2018083085A1 (en) *	2016-11-02	2018-05-11	F. Hoffmann-La Roche Ag	PYRAZOLO[1,5a]PYRIMIDINE DERIVATIVES AS IRAK4 MODULATORS
IL317854A (en) *	2017-07-28	2025-02-01	Takeda Pharmaceuticals Co	TYK2 inhibitors and their uses
EP3661919A4 (en)	2017-08-02	2021-03-31	Northwestern University	SUBSTITUTED FUSION PYRIMIDINE COMPOUNDS AND THEIR USES
AU2018346597B2 (en)	2017-10-06	2023-07-13	Forma Therapeutics, Inc.	Inhibiting Ubiquitin Specific Peptidase 30
EP3747885A4 (en)	2018-01-31	2021-11-03	Takeda Pharmaceutical Company Limited	HETEROCYCLIC COMPOUND
IL278291B2 (en)	2018-05-17	2023-10-01	Forma Therapeutics Inc	Condensed bicyclic compounds are useful as ubiquitin-specific peptidase 30 inhibitors
US10882865B2 (en)	2018-08-31	2021-01-05	Northwestern University	Pyrrolopyrimidine compounds and uses thereof for modulating glucocerebrosidase activity
EP3849981B1 (en)	2018-09-10	2023-02-01	Eli Lilly and Company	Pyrazolo[1,5-a]pyrimidine-3-carboxamide derivatives useful in the treatment of psoriasis and systemic lupus erythematosus
EP4218934B1 (en)	2018-10-05	2025-06-18	Forma Therapeutics, Inc.	Inhibiting ubiquitin-specific protease 30 (usp30)
JP7619951B2 (ja) *	2018-10-15	2025-01-22	武田薬品工業株式会社	Ｔｙｋ２阻害剤およびその使用
TWI800696B (zh)	2018-12-10	2023-05-01	美商美國禮來大藥廠	7-(甲基胺基)吡唑并[1,5-a]嘧啶-3-甲醯胺衍生物
CA3151850A1 (en) *	2019-08-21	2021-02-25	The Scripps Research Institute	Bicyclic agonists of stimulator of interferon genes (sting)
CA3150700A1 (en)	2019-09-17	2021-03-25	Renato T. Skerlj	IMIDAZOLE SUBSTITUTE CARBOXAMIDES AND THEIR USE IN THE TREATMENT OF MEDICAL DISORDERS
CN114901652A (zh)	2019-09-17	2022-08-12	比亚尔R&D投资股份公司	用于治疗医学病症的经取代的饱和和不饱和n-杂环甲酰胺及相关化合物
CA3151022A1 (en)	2019-09-17	2021-03-25	Bial - R&D Investments, S.A.	Substituted n-heterocyclic carboxamides as acid ceramidase inhibitors and their use as medicaments
JP7890737B2 (ja) *	2019-11-25	2026-07-15	ジーティーゲインセラピューティクスエスアー	ガラクトセレブロシダーゼの活性の変質に関連する状態におけるアリールおよびヘテロアリール化合物、ならびにそれらの治療的使用
TWI810520B (zh)	2020-02-12	2023-08-01	美商美國禮來大藥廠	7-(甲基胺基)吡唑并[1,5-a]嘧啶-3-甲醯胺化合物
CA3167313A1 (en)	2020-02-12	2021-08-19	Thomas John Bleisch	Substituted 7-(methylamino)pyrazolo[1,5-a]pyrimidine-3-carboxamide derivatives
US20250230172A1 (en) *	2021-10-13	2025-07-17	Vanqua Bio, Inc.	Small molecule modulators of glucocerebrosidase activity and uses thereof
CA3235270A1 (en) *	2021-10-13	2023-04-20	Vanqua Bio, Inc.	Small molecule modulators of glucocerebrosidase activity and uses thereof

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO2004037373A2 (en)	2002-10-21	2004-05-06	The Scripps Research Institute	CHEMICAL CHAPERONES AND THEIR EFFECT UPON THE CELLULAR ACTIVITY OF β-GLUCOSIDASE
JP2004277337A (ja) *	2003-03-14	2004-10-07	Sumitomo Pharmaceut Co Ltd	ピラゾロ［１，５−ａ］ピリミジン誘導体
EP1615697A2 (en) *	2003-04-11	2006-01-18	Novo Nordisk A/S	New pyrazolo[1,5-a] pyrimidine derivatives and pharmaceutical use thereof
US20050137223A1 (en)	2003-11-12	2005-06-23	Amicus Therapeutics, Inc.	Glucoimidazole and polyhydroxycyclohexenyl amine derivatives to treat gaucher disease
CA2507348C (en) *	2004-05-13	2013-07-16	The Hospital For Sick Children	Real time methylumbelliferone-based assay
EP1753422B1 (en)	2004-05-14	2008-05-28	The Cleveland Clinic Foundation	Small molecule inhibitors for mrp1 and other multidrug transporters
ATE383361T1 (de) *	2004-06-21	2008-01-15	Hoffmann La Roche	Pyrrazolopyrimidinderivate
DE102005007534A1 (de) *	2005-02-17	2006-08-31	Bayer Cropscience Ag	Pyrazolopyrimidine
US20070155737A1 (en)	2005-05-20	2007-07-05	Alantos Pharmaceuticals, Inc.	Heterobicyclic metalloprotease inhibitors
JP5463034B2 (ja)	2005-05-20	2014-04-09	アラントス・フアーマシユーテイカルズ・ホールデイング・インコーポレイテツド	ピリミジン若しくはトリアジン縮合二環式メタロプロテアーゼ阻害薬
WO2007008541A2 (en)	2005-07-08	2007-01-18	Kalypsys, Inc.	Cellular cholesterol absorption modifiers
MX2008002014A (es) *	2005-08-15	2008-03-27	Hoffmann La Roche	Derivados de piperidina y piperazina como antagonistas de p2x3.
CA2626789A1 (en) *	2005-10-21	2007-04-26	Exelixis, Inc.	Pyrimidinones as casein kinase ii (ck2) modulators
US8188097B2 (en) *	2005-10-21	2012-05-29	Mitsubishi Tanabe Pharma Corporation	Pyrazolo[1,5-A]pyrimidine compounds
WO2008054947A2 (en)	2006-10-02	2008-05-08	The Brigham And Women's Hospital, Inc.	Structure of acid beta-glucosidase and methods for identifying therapeutic agents
WO2008045664A2 (en)	2006-10-06	2008-04-17	Kalypsys, Inc.	Heterocyclic pde4 inhibitors as antiinflammatory agents
US20080176870A1 (en)	2006-11-20	2008-07-24	Bert Nolte	Heterobicyclic metalloprotease inhibitors
MX2009011055A (es)	2007-04-13	2010-01-13	Amicus Therapeutics Inc	Tratamiento de la enfermedad de gaucher con chaperonas farmacologicas especificas y supervision del tratamiento utilizando marcadores sustitutos.
WO2008134035A1 (en)	2007-04-27	2008-11-06	Panacos Pharmaceuticals, Inc.	Alpha-unsubstituted arylmethyl piperazine pyrazolo[1,5-a] pyrimidine amide derivatives
CN104383556B (zh)	2007-05-16	2018-06-05	布里格姆妇女医院	突触核蛋白病的治疗
US20090118135A1 (en)	2007-06-08	2009-05-07	The Burnham Institute	Methods and compounds for regulating apoptosis
JP5337405B2 (ja)	2007-09-17	2013-11-06	ザ・ホスピタル・フォー・シック・チルドレン	ゴーシェ病の治療方法
WO2009049422A1 (en)	2007-10-18	2009-04-23	The Hospital For Sick Children	Compositions and methods for enhancing enzyme activity in gaucher, gm1 -gangliosidosis/morquio b disease. and parkinson's disease
AU2008345225A1 (en) *	2007-12-21	2009-07-09	University Of Rochester	Method for altering the lifespan of eukaryotic organisms
CN104530052A (zh) *	2008-06-10	2015-04-22	普莱希科公司	用于激酶调节的5h-吡咯[2,3-b]吡嗪衍生物和其适应症
EP2307440A4 (en)	2008-07-01	2012-12-19	Zacharon Pharmaceuticals Inc	HEPARAN SULFATE INHIBITORS
WO2010086040A1 (en) *	2009-01-29	2010-08-05	Biomarin Iga, Ltd.	Pyrazolo-pyrimidines for treatment of duchenne muscular dystrophy
PL3366688T3 (pl) *	2010-12-08	2022-05-23	The U.S.A. As Represented By The Secretary, Department Of Health And Human Services	Podstawione pirazolopirymidyny jako aktywatory glukocerebrozydazy
EP3215511B1 (en) *	2014-11-06	2024-04-17	Bial-R&D Investments, S.A.	Substituted pyrazolo(1,5-a)pyrimidines and their use in the treatment of medical disorders

2011
- 2011-12-08 PL PL18165005T patent/PL3366688T3/pl unknown
- 2011-12-08 SI SI201131532T patent/SI2649075T1/sl unknown
- 2011-12-08 WO PCT/US2011/063928 patent/WO2012078855A1/en not_active Ceased
- 2011-12-08 RS RS20220422A patent/RS63320B1/sr unknown
- 2011-12-08 CA CA2820362A patent/CA2820362C/en active Active
- 2011-12-08 TR TR2018/10523T patent/TR201810523T4/tr unknown
- 2011-12-08 MX MX2018000385A patent/MX385600B/es unknown
- 2011-12-08 CN CN201180066859.7A patent/CN103534255B/zh active Active
- 2011-12-08 PT PT181650052T patent/PT3366688T/pt unknown
- 2011-12-08 HR HRP20220512TT patent/HRP20220512T1/hr unknown
- 2011-12-08 ES ES18165005T patent/ES2912284T3/es active Active
- 2011-12-08 AU AU2011338377A patent/AU2011338377B2/en active Active
- 2011-12-08 EP EP18165005.2A patent/EP3366688B1/en active Active
- 2011-12-08 RU RU2013126094/04A patent/RU2603637C2/ru active
- 2011-12-08 KR KR1020137017520A patent/KR101931224B1/ko active Active
- 2011-12-08 MX MX2013006462A patent/MX354506B/es active IP Right Grant
- 2011-12-08 EP EP11810714.3A patent/EP2649075B1/en active Active
- 2011-12-08 JP JP2013543335A patent/JP6154746B2/ja active Active
- 2011-12-08 ES ES11810714.3T patent/ES2681218T3/es active Active
- 2011-12-08 PT PT118107143T patent/PT2649075T/pt unknown
- 2011-12-08 DK DK11810714.3T patent/DK2649075T3/en active
- 2011-12-08 SI SI201132052T patent/SI3366688T1/sl unknown
- 2011-12-08 PL PL11810714T patent/PL2649075T3/pl unknown
- 2011-12-08 BR BR112013014242-1A patent/BR112013014242B1/pt active IP Right Grant
- 2011-12-08 DK DK18165005.2T patent/DK3366688T3/da active
- 2011-12-08 HU HUE11810714A patent/HUE038635T2/hu unknown
- 2011-12-08 US US13/991,816 patent/US9353117B2/en active Active
- 2011-12-08 LT LTEP18165005.2T patent/LT3366688T/lt unknown
2013
- 2013-06-06 IL IL226767A patent/IL226767B/en active IP Right Grant
- 2013-06-07 ZA ZA2013/04215A patent/ZA201304215B/en unknown
2016
- 2016-04-28 US US15/141,275 patent/US9974789B2/en active Active
2018
- 2018-05-18 US US15/983,844 patent/US10925874B2/en active Active
- 2018-05-28 IL IL259648A patent/IL259648B/en active IP Right Grant
2022
- 2022-05-04 CY CY20221100316T patent/CY1125186T1/el unknown

Also Published As

Publication number	Publication date
SI3366688T1 (sl)	2022-07-29
US9353117B2 (en)	2016-05-31
IL226767B (en)	2018-06-28
PT3366688T (pt)	2022-05-11
ZA201304215B (en)	2014-03-26
CN103534255B (zh)	2016-12-21
KR101931224B1 (ko)	2018-12-20
TR201810523T4 (tr)	2018-08-27
CY1125186T1 (el)	2024-12-13
BR112013014242A2 (pt)	2018-06-26
EP3366688B1 (en)	2022-02-09
PT2649075T (pt)	2018-07-30
AU2011338377B2 (en)	2016-08-04
EP2649075A1 (en)	2013-10-16
CN103534255A (zh)	2014-01-22
US20140249145A1 (en)	2014-09-04
KR20140010012A (ko)	2014-01-23
US20160346284A1 (en)	2016-12-01
US9974789B2 (en)	2018-05-22
ES2912284T3 (es)	2022-05-25
ES2681218T3 (es)	2018-09-12
JP2013544893A (ja)	2013-12-19
MX2013006462A (es)	2013-10-01
MX385600B (es)	2025-03-18
IL259648A (en)	2018-07-31
WO2012078855A1 (en)	2012-06-14
HUE038635T2 (hu)	2018-11-28
AU2011338377A8 (en)	2015-10-29
LT3366688T (lt)	2022-05-25
RU2603637C2 (ru)	2016-11-27
AU2011338377A1 (en)	2013-07-04
HRP20220512T1 (hr)	2022-05-27
RS63320B1 (sr)	2022-07-29
JP6154746B2 (ja)	2017-06-28
DK3366688T3 (da)	2022-05-02
US10925874B2 (en)	2021-02-23
RU2013126094A (ru)	2015-01-20
PL2649075T3 (pl)	2018-09-28
IL259648B (en)	2021-03-25
DK2649075T3 (en)	2018-07-30
EP3366688A1 (en)	2018-08-29
CA2820362A1 (en)	2012-06-14
MX354506B (es)	2018-01-16
SI2649075T1 (sl)	2018-10-30
BR112013014242B1 (pt)	2022-02-22
CA2820362C (en)	2020-03-24
US20180263988A1 (en)	2018-09-20
EP2649075B1 (en)	2018-04-25

Publication	Publication Date	Title
IL259648B (en)	2021-03-25	Pyrazolopyrimidines are metabolized as glucocerebrosidase enzymes
AP3607A (en)	2016-02-26	Substituted imidazopyridazines
IL222646A0 (en)	2012-12-31	N3-substituted -n1-sulfonyl-5-fluoropyrimidinone derivatives
PL2534132T3 (pl)	2017-09-29	Podstawione pirolidyno-2-karboksyamidy
ZA201209117B (en)	2013-09-25	Tetrahydro-pyrido-pyrimidine derivatives
EP2534256A4 (en)	2013-07-24	NEW USES
IL226192A0 (en)	2013-07-31	Modified sodium-1h-pyrazole-5-oleate
EP2541164A4 (en)	2016-09-07	COOLER
GB2490849B (en)	2020-01-01	Di-aspirin derivatives
IL225312A0 (en)	2013-06-27	New combinations
HUP1000243A2 (en)	2012-01-30	8-hidroxy-quinoline derivatives
AU4538P (en)	2013-05-16	H22 Grevillea juniperina
AU332681S (en)	2010-09-08	Spindle
GB201008355D0 (en)	2010-07-07	Solid supports
ZA201209248B (en)	2013-08-28	Amido-tropane derivatives
IL220983A0 (en)	2012-09-24	2-aldoximino-5-fluoropyrimidine derivatives
GB201019442D0 (en)	2010-12-29	Novel combinations
AU2010900285A0 (en)	2010-02-11	Sparger
GB201002000D0 (en)	2010-03-24	Formulation